Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012205
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company’s proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Licensing Agreements 14
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Equity Offering 17
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Asset Transactions 30
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp – Key Competitors 32
Helix BioPharma Corp – Key Employees 33
Helix BioPharma Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 37
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 39
Dec 13, 2016: Helix BioPharma Announces Fiscal First Quarter 2017 Results 40
Oct 31, 2016: Helix BioPharma Announces Fiscal 2016 Results 41
Jun 14, 2016: Helix BioPharma Announces Third Quarter Fiscal 2016 Results 42
Mar 16, 2016: Helix Biopharma Announces Second Quarter Fiscal 2016 Results 43
Corporate Communications 44
Dec 01, 2017: Helix BioPharma Announces Management Change 44
Jul 17, 2017: Helix BioPharma Director Resigns 45
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 46
Sep 07, 2016: Helix BioPharma Announces New Director Appointment 47
Apr 20, 2016: Helix BioPharma Announces Important Additions to Its Leadership Team 48
Mar 29, 2016: Helix BioPharma Announces CEO Change 49
Feb 04, 2016: Changes in the Leadership of Helix Polska 50
Jan 29, 2016: Helix BioPharma Announces Appointment of New Directors to the Board of Directors 51
Jan 12, 2016: Helix BioPharma Announces Appointment of Permanent New CEO and Changes at Board Level 52
Product News 53
10/19/2016: Helix BioPharma Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy 53
07/21/2016: Helix BioPharma, Subsidiary, Helix Polska, Finalizes Grant Funding With the Polish National Center for Research and Development 54
05/09/2016: Helix BioPharma Subsidiary, Helix Polska Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development 55
Other Significant Developments 56
Jun 02, 2016: Helix BioPharma Appoints Evolution Life Science Partners as Advisors 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp, Key Competitors 32
Helix BioPharma Corp, Key Employees 33
Helix BioPharma Corp, Subsidiaries 34

★海外企業調査レポート[Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Salzgitter Klockner-Werke GmbH:企業の戦略・SWOT・財務情報
    Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report Summary Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Basin Electric Power Cooperative:発電所・企業SWOT分析
    Basin Electric Power Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Electrica SA (EL):企業の財務・戦略的SWOT分析
    Electrica SA (EL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ecsponent Limited (ECS):企業の財務・戦略的SWOT分析
    Ecsponent Limited (ECS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Babcock & Wilcox Enterprises Inc (BW):電力:M&Aディール及び事業提携情報
    Summary Babcock & Wilcox Enterprises, Inc. (Babcock & Wilcox) is a provider of technology-based advanced fossil and renewable power generation and environmental equipment. The company offers a range of biomass-fired boilers products such as supercritical boiler, waste-to-energy boilers, heat recover …
  • Aushon BioSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that provides biomarker measurement and analysis products. The company offers biomarker therapeutic areas in microarray printing technology. It provides products such as ciraplex assay, cirascan imaging and cirasoft analysis and cir …
  • Pearson plc (PSON):企業の財務・戦略的SWOT分析
    Pearson plc (PSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Atmos Energy Corporation (ATO):石油・ガス:M&Aディール及び事業提携情報
    Summary Atmos Energy Corp (Atmos Energy) is a fully-regulated natural gas distributor. Together with its subsidiaries, the company delivers natural gas through regulated sales and transportation arrangements to residential, commercial, public authority and industrial customers.The company is also in …
  • Banco Santander SA:戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Infineum International Ltd:企業の戦略的SWOT分析
    Infineum International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Guy’s and St Thomas’ NHS Foundation Trust:企業の戦略的SWOT分析
    Guy's and St Thomas' NHS Foundation Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • John Wood Group Plc (WG.):企業の財務・戦略的SWOT分析
    John Wood Group Plc (WG.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ImpediMed Ltd (IPD):企業の財務・戦略的SWOT分析
    ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • CRA International Inc (CRAI):企業の財務・戦略的SWOT分析
    Summary CRA International Inc (CRA) is a consulting firm that offers economic, financial, and strategic expertise to law firms, corporations, accounting firms and governments. The firm provides services such as accounting and forensic services, antitrust and competition, auctions and competitive bid …
  • Compal Electronics, Inc.:企業の戦略・SWOT・財務分析
    Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary Compal Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Dillard’s Inc:戦略・SWOT・企業財務分析
    Dillard's Inc - Strategy, SWOT and Corporate Finance Report Summary Dillard's Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Biomunex Pharmaceuticals:製薬・医療:M&Aディール及び事業提携情報
    Summary Biomunex Pharmaceuticals (Biomunex) is a biopharmaceutical company that discovers and develops bispecific antibody therapeutics for the treatment of cancer. The company’s portfolio of pipeline products incldes BMX-101, which is developed as a novel immunotherapeutic treatment for relapsed an …
  • Avient Corp (POL):企業の財務・戦略的SWOT分析
    Avient Corp (POL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆